Become one of the exclusive 30 investors taking DAVIGOworx public! Secure your place in the consortium now.
The investment company DAVIGOworx GmbH & Co KGaA is on the verge of a significant step: It is offering a "stock exchange-ready" share for issuance, whose investment strategy is fully developed and tested. To realize the successful IPO in the premium over-the-counter market plus XETRA, DAVIGOworx is forming a consortium of 30 investors who will provide capital for drawdown as part of a private placement.
Completed investments
from the practical test portfolio*
DECIPHERA PHARMACEUTICALS IN
NEOGAMES SA
HIBBETT INC
ALPINE IMMUNE SCIENCES INC
SHOCKWAVE MEDICAL INC
SOVOS BRANDS INC
TEXTAINER GROUP HOLDINGS LTD
DISCOVER FINANCIAL SERVICES
MASONITE INTERNATIONAL CORP
CYMABAY THERAPEUTICS INC
MCGRATH RENTCORP
QIAGEN N.V.
OVERSEAS SHIPHOLDING GROUP-A
ENGAGESMART INC
INHIBRX INC
KAMAN CORP
MDC HOLDINGS INC
CARROLS RESTAURANT GROUP INC
FIRST FINANCIAL NORTHWEST
ANSYS INC
JUNIPER NETWORKS INC
AXONICS INC
ENETI INC
DASEKE INC
KARUNA THERAPEUTICS INC
CEREVEL THERAPEUTICS HOLDING
ALTERYX INC - CLASS A
PGT INNOVATIONS INC
UNITED STATES STEEL CORP
ICOSAVAX INC
IMMUNOGEN INC
VERITIV CORP
ROVER GROUP INC
VMWARE INC-CLASS A
ARGO GROUP INTERNATIONAL
NEW RELIC INC
BLUEGREEN VACATIONS HOLDING
TABULA RASA HEALTHCARE INC
SPIRIT REALTY CAPITAL INC
FIESTA RESTAURANT GROUP
CIRCOR INTERNATIONAL INC
HERITAGE-CRYSTAL CLEAN INC
ACTIVISION BLIZZARD INC
NATIONAL INSTRUMENTS CORP
PIONEER NATURAL RESOURCES CO
MIRATI THERAPEUTICS INC
NATIONAL WESTERN LIFE GROU-A
SP PLUS CORP
HORIZON THERAPEUTICS PLC
LIVEVOX HOLDINGS INC
*Past returns are not an indicator of future returns.
For the acquisition of publicly listed company shares, DAVIGOworx utilizes its self-developed software "Yield Finder." This investment technology has been extensively used in a practical test portfolio since August 2018. Since then, a total of 2,222 company shares (as of April 30, 2024) have been acquired and subsequently sold – with very positive results. The average profit per sold company share in the practical test portfolio was 62.6 percent as of April 30, 2024, with an average holding period per company share of 2.1 years. This corresponds to an average of 25.4 percent p.a. per investment. These were almost exclusively U.S. companies included in broad U.S. indices.
DAVIGOworx revolutionizes the investment market with a unique publicly traded share that innovatively combines Public and Private Equity.
We will bundle thousands of company investments in a single, liquid security, making diversified investing accessible to all.
Our data-driven approach combines the strengths of Public and Private Equity: while we primarily focus on small and mid-caps in the Public Equity sector, a balanced portfolio across vintages, stages, regions, and sectors will emerge in the Private Equity segment - in collaboration with VC/PE experts.
This agile combination of both asset classes will enable stabilization and maximization of capital efficiency with daily tradability - a decisive advantage over traditionally illiquid PE investments.
The transparency and easy integration into existing investment guidelines make us particularly attractive to institutional investors, while private investors benefit from the ability to comprehensively diversify their portfolio with a single share.
Our goal is to establish the DAVIGOworx share as an indispensable component in every investor's portfolio. Become part of the DAVIGOworx investor consortium and shape the future of diversified investing with us - with a scalable, future-oriented investment solution that redefines the boundaries between Public and Private Equity.
Questions and Answers
DAVIGOworx is the revolutionary stock that will unite Public and Private Equity in a single, liquid security. Thousands of company investments, a data-driven approach, and daily tradability will make DAVIGOworx the future of diversified investing. Whether you're a private investor or an institutional investor - with DAVIGOworx, you'll experience how we redefine the boundaries of traditional asset classes and take every (!) portfolio to the next level.
Our primary goal is initially to enter the premium over-the-counter market plus XETRA. However, this is just the beginning: We are striving to switch to the regulated market as quickly as possible to further strengthen our market position and become attractive to an even broader spectrum of investors.
The path to the stock exchange follows clearly defined steps. First, we form a consortium of 30 investors who provide capital for drawdown as part of a private placement. Once the stock exchange admission criteria for the premium over-the-counter market are met, we will call on the capital commitments, with which the investors will subscribe to the DWRX24 shares. The listing will take place a few days later. The collected capital will flow exclusively into portfolio building and growth-promoting measures.
After the IPO, we will focus on a strategy of continuous growth. We plan regular capital increases, supported by massive marketing towards retail investors and targeted engagement with institutional partners such as issuing banks and selling agents. Our goal is to steadily increase the liquidity of DAVIGOworx stock and make it attractive to an increasingly broader range of investor groups.
Yes, the initial members of the consortium have the exclusive opportunity to participate directly in DAVIGOworx Management GmbH, provided certain requirements are met. This is the fintech behind DAVIGOworx and potentially offers significant growth opportunities.
We have established a clear process to protect the interests of all parties involved. The capital will only be called once all 30 consortium partners are secured and the stock exchange listing requirements are met. This ensures that we can enter the market with the necessary strength and capital.
Note
The information on this website represents promotional preliminary information for a planned public offering of shares by DAVIGOworx GmbH & Co. KGaA in the form of a private placement using the prospectus exemption under Art. 1 Para. 4 lit c) Regulation (EU) 2017/1129. The standard minimum subscription amount shall be EUR 1 million, in no case less than EUR 100,000. The information on this website is not sufficient to make a purchase decision and does not replace complete and final information from DAVIGOworx GmbH & Co. KGaA. Therefore, the information on this website does not constitute an offer to purchase shares.
Warning: The acquisition of shares involves substantial risks and may lead to the complete loss of invested capital.